Tilray (TLRY) in Focus: Stock Moves 9% HigherHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Tilray (TLRY) in Focus: Stock Moves 9% HigherZacks Equity ResearchZacksJanuary 2, 2020ReblogShareTweetShareTilray, Inc. TLRY was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 13.7% in the past one-month time frame.The company has seen six negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.Tilray currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.  Tilray, Inc. PriceTilray, Inc. PriceMoreTilray, Inc. price | Tilray, Inc. QuoteA better-ranked stock in the Medical – Drugs industry is Actinium Pharmaceuticals, Inc. ATNM, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Is TLRY going up? Or down? Predict to see what others think: Up or Down7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.See 7 handpicked stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Actinium Pharmaceuticals, Inc. (ATNM) : Free Stock Analysis Report Tilray, Inc. (TLRY) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextTop Marijuana Stocks for March 2020InvestopediaRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHow Does China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512) Stand Up To These Simple Dividend Safety Checks?Simply Wall St.Don’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDow Jones Futures Fall As Coronavirus Stock Market Correction Intensifies; Tesla, Nvidia, Beyond Meat Down LateInvestor's Business DailyStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance